News
CVM
--
0.00%
--
We Think CEL-SCI (NYSEMKT:CVM) Can Afford To Drive Business Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Simply Wall St. · 6d ago
T Cell Surface Glycoprotein CD4 Market Emerging Trends, Business Enlargement Plans Forecast 2020-2027 |Ameco Research
pune, India, Tue, 23 Mar 2021 02:39:56 / Comserve Inc. / -- Global T Cell Surface Glycoprotein CD4 Market Report Covers Market Statistics, Latest Trends Amid...
Comserve · 03/23 06:42
Smallpox Vaccine Market Overview, Industry Trends and Growing Opportunities Till 2027
Mar 10, 2021 (Market Insight Reports) -- The latest report as Smallpox Vaccine Market acknowledges Size, Application Segment, Type, Regional Outlook, Market...
Market Insight Reports · 03/10 07:56
Biotech CEL-SCI Needs More Base Building
During Friday's "Lightning Round" segment of Mad Money, one caller asked Jim Cramer about the biotech firm CEL-SCI Corp : "I think this one is good," responded Cramer. In this daily bar chart of CVM, below, we can see that prices traded sideways in the $...
TheStreet.com · 03/09 11:17
Cramer Gives His Opinion On Equinix, Walgreens Boots Alliance And CEL-SCI
Jim Cramer said on CNBC's "Mad Money Lightning Round" that Equinix Inc (NASDAQ: EQIX) is a real estate investment trust and right now, with the interest rates going higher, people don'
Benzinga · 03/05 12:53
Cramer's lightning round: I cannot recommend Equinix
"Mad Money" host Jim Cramer rings the lightning round bell, which means he's giving his answers to callers' stock questions at rapid speed.
CNBC.com · 03/05 00:50
CVM: 1Q:21 Financial Update
By John Vandermosten, CFA NYSE:CVM First Quarter Fiscal Year 2021 Operational and Financial Results CEL-SCI Corporation (NYSE:CVM) posted a press release and filed its 10-Q for its first quarter of fiscal year 2021 in mid-February. Since our previous repor...
Zacks Small Cap Research · 03/01 10:15
BRIEF-CEL-SCI Corporation Reports First Quarter Fiscal 2021 Financial Results
reuters.com · 02/16 14:21
Cel-Sci reports FQ1 results
Cel-Sci (CVM): FQ1 GAAP EPS of -$0.21.Cash position was ~$21.9M. After Dec. 31, 2020, CEL-SCI has received ~$3.9M through the exercise of warrants and stock options.Shares +1.91% PM.Press Release
Seekingalpha · 02/16 14:10
CEL-SCI Q1 EPS $(0.21) Down From $(0.16) YoY
CEL-SCI (AMEX:CVM) reported quarterly losses of $(0.21) per share. This is a 31.25 percent decrease over losses of $(0.16) per share from the same period last year.
Benzinga · 02/16 14:05
CEL-SCI 1Q Loss/Shr 21c >CVM
CEL-SCI 1Q Loss/Shr 21c >CVM
Dow Jones · 02/16 14:00
Press Release: CEL-SCI Corporation Reports First Quarter Fiscal 2021 Financial Results
Dow Jones · 02/16 14:00
West Nile Virus Testing Market Global Trends, Market Share, Industry Size, Growth, Opportunities and Market Forecast 2020 to 2027
Feb 16, 2021 (Market Insight Reports) -- The report for West Nile Virus Testing offers an assiduous analysis of contemporary market trends, driving factors,...
Market Insight Reports · 02/16 13:45
Tyme Technologies, GW Pharmaceuticals leads healthcare gainers; Vaxart, Moleculin Biotech among major losers
Gainers: Tyme Technologies TYME +110%, GW Pharmaceuticals GWPH +47%, Zynerba Pharmaceuticals ZYNE +39%, SELLAS Life Sciences SLS +38%, InMed Pharmaceuticals (INM) +15%.Losers: Vaxart VXRT -51%, Moleculin Biotech (MBRX) -26%, Ocugen (OCGN) -16%, CEL-SCI Cor...
Seekingalpha · 02/03 16:02
West Nile Virus Infections Medicine Market 2021 by Growing Demands, Sales, Revenue, Gross Margin, Geographical Regions, and Forecast to 2027
Feb 03, 2021 (The Expresswire) -- "Final Report will add the analysis of the impact of COVID-19 on this industry." “West Nile Virus Infections Medicine...
The Express Wire · 02/03 08:37
AG, GME, AAL and IRDM among premarket gainers
JanOne (JAN) +166%.Koss (KOSS) +155%.Monopar Therapeutics (MNPR) +130%.Naked Brand Group (NAKD) +101% on $50M direct offering.AeroCentury (ACY) +83%.Sundial Growers (SNDL) +64%.American Airlines Group (AAL) +58% on Q4 results.Chico's FAS (CHS) +47%.First M...
Seekingalpha · 01/28 13:27
Covid-19 Impact: Poxviridae Infections Drug Market To Grow At A Much Faster Rate Beyond 2020| Financial Analysis And Forecast
Jan 28, 2021 (MarketResearch.biz via Comtex) -- Poxviridae Infections Drug Businesses must navigate the financial and operational challenges of coronavirus...
marketresearch.biz · 01/28 09:25
CEL-SCI climbs as CEO tweets ‘after $GME, big changes are coming’
The small-cap biotech, CEL-SCI Corporation (CVM) has more than doubled in value in the day so far on record volume with ~16.3x of the 65-day average daily volume of shares
Seekingalpha · 01/27 18:06
TTOO, NOK, RIG and PBI among midday movers
Gainers: Express (EXPR) +278%.Koss (KOSS) +242%.AMC Entertainment (AMC) +184%.GameStop (GME) +124%.Fossil Group (FOSL) +121%.CEL-SCI (CVM) +83%.Naked Brand (NAKD) +80%.Nokia (NOK) +42%.Transocean (RIG) +38%.Vir Biotechnology (VIR) +34%.Losers: 1847 Goedeke...
Seekingalpha · 01/27 17:41
CVM: Fiscal Year 2020 Results
Zacks Small Cap Research · 01/11 10:21
Webull provides a variety of real-time CVM stock news. You can receive the latest news about CEL SCI through multiple platforms. This information may help you make smarter investment decisions.
About CVM
CEL-SCI Corporation is engaged in the research and development at developing the treatment of cancer and other diseases by using the immune system. The Company is focused on activating the immune system to fight cancer and infectious diseases. It operates through the segment of research and development of certain drugs and vaccines. It is focused on the development of Multikine (Leukocyte Interleukin, Injection), an investigational immunotherapy under development for treatment of certain head and neck cancers, and anal warts or cervical dysplasia in human immunodeficiency virus and human papillomavirus co-infected patients and Ligand Epitope Antigen Presentation System (L.E.A.P.S.) technology, with over two investigational therapies, LEAPS-H1N1-DC, a product candidate under development for treatment of pandemic influenza in hospitalized patients, and CEL-2000 and CEL-4000, vaccine product candidates under development for treatment of rheumatoid arthritis.